公开(公告)号：US09751887B2

公开(公告)日：2017-09-05

申请号：US14926973

申请日：2015-10-29

申请人： Daiichi Sankyo Company, Limited

发明人： Yasuyuki Takeda ,  Kenji Yoshikawa ,  Yoshiko Kagoshima ,  Yuko Yamamoto ,  Ryoichi Tanaka ,  Yuichi Tominaga ,  Masaki Kiga ,  Yoshito Hamada

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

公开(公告)号：US11236106B2

公开(公告)日：2022-02-01

申请号：US17243360

申请日：2021-04-28

申请人： Daiichi Sankyo Company, Limited

发明人： Kenji Yoshikawa ,  Noriyasu Haginoya ,  Tomoaki Hamada ,  Ryutaro Kanada ,  Jun Watanabe ,  Yoshiko Kagoshima ,  Eri Tokumaru ,  Kenji Murata ,  Takayuki Baba ,  Mayumi Kitagawa ,  Akiko Kurimoto ,  Masashi Numata ,  Machiko Shiroishi ,  Taeko Shinozaki

IPC分类号： C07D495/04 ,  A61P35/02 ,  A61K45/06

摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

公开(公告)号：US20210269454A1

公开(公告)日：2021-09-02

申请号：US17243360

申请日：2021-04-28

申请人： Daiichi Sankyo Company, Limited

发明人： Kenji Yoshikawa ,  Noriyasu Haginoya ,  Tomoaki Hamada ,  Ryutaro Kanada ,  Jun Watanabe ,  Yoshiko Kagoshima ,  Eri Tokumaru ,  Kenji Murata ,  Takayuki Baba ,  Mayumi Kitagawa ,  Akiko Kurimoto ,  Masashi Numata ,  Machiko Shiroishi ,  Taeko Shinozaki

IPC分类号： C07D495/04 ,  A61K45/06 ,  A61P35/02

摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

公开(公告)号：US09187489B2

公开(公告)日：2015-11-17

申请号：US14378318

申请日：2013-06-03

申请人： Daiichi Sankyo Company, Limited

发明人： Yasuyuki Takeda ,  Kenji Yoshikawa ,  Yoshiko Kagoshima ,  Yuko Yamamoto ,  Ryoichi Tanaka ,  Yuichi Tominaga ,  Masaki Kiga ,  Yoshito Hamada

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

摘要翻译： 本发明旨在提供其可用于通过其ROS1激酶活性抑制作用和NTRK激酶抑制作用治疗肿瘤的化合物或其药理学上可接受的盐。 本发明提供具有由通式（I）表示的咪唑并[1,2-b]哒嗪结构或其药学上可接受的盐的化合物和包含该化合物的药物组合物。 在该式中，R1，G，T，Y1，Y2，Y3和Y4如本文所定义。

公开(公告)号：US20230074669A1

公开(公告)日：2023-03-09

申请号：US17535369

申请日：2021-11-24

申请人： Daiichi Sankyo Company, Limited

发明人： Kenji Yoshikawa ,  Noriyasu Haginoya ,  Tomoaki Hamada ,  Ryutaro Kanada ,  Jun Watanabe ,  Yoshiko Kagoshima ,  Eri Tokumaru ,  Kenji Murata ,  Takayuki Baba ,  Mayumi Kitagawa ,  Akiko Kurimoto ,  Masashi Numata ,  Machiko Shiroishi ,  Taeko Shinozaki

IPC分类号： C07D495/04 ,  A61P35/02 ,  A61K45/06

摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

公开(公告)号：US20230030720A1

公开(公告)日：2023-02-02

申请号：US17289710

申请日：2019-12-05

申请人： Daiichi Sankyo Company, Limited

发明人： Kenji Yoshikawa ,  Noriyasu Haginoya ,  Tomoaki Hamada ,  Ryutaro Kanada ,  Jun Watanabe ,  Yoshiko Kagoshima ,  Eri Tokumaru ,  Kenji Murata ,  Takayuki Baba ,  Mayumi Kitagawa ,  Akiko Kurimoto ,  Masashi Numata ,  Machiko Shiroishi ,  Taeko Shinozaki

IPC分类号： C07D495/04 ,  C07D519/00 ,  C07D403/12 ,  C07D403/14 ,  A61K45/06

摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

公开(公告)号：US20160046639A1

公开(公告)日：2016-02-18

申请号：US14926973

申请日：2015-10-29

申请人： Daiichi Sankyo Company, Limited

发明人： Yasuyuki Takeda ,  Kenji Yoshikawa ,  Yoshiko Kagoshima ,  Yuko Yamamoto ,  Ryoichi Tanaka ,  Yuichi Tominaga ,  Masaki Kiga ,  Yoshito Hamada

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

公开(公告)号：US20150051190A1

公开(公告)日：2015-02-19

申请号：US14378318

申请日：2013-06-03

申请人： Daiichi Sankyo Company, Limited

发明人： Yasuyuki Takeda ,  Kenji Yoshikawa ,  Yoshiko Kagoshima ,  Yuko Yamamoto ,  Ryoichi Tanaka ,  Yuichi Tominaga ,  Masaki Kiga ,  Yoshito Hamada

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

摘要翻译： 本发明旨在提供其可用于通过其ROS1激酶活性抑制作用和NTRK激酶抑制作用治疗肿瘤的化合物或其药理学上可接受的盐。 本发明提供具有由通式（I）表示的咪唑并[1,2-b]哒嗪结构或其药学上可接受的盐的化合物和包含该化合物的药物组合物。 在该式中，R1，G，T，Y1，Y2，Y3和Y4如本文所定义。